US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Sagimet Biosciences Inc.

< Previous 1 2 3 Next >
News headline image
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Provides Strategic and Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers OMER SGMT
News headline image
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
News headline image
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
< Previous 1 2 3 Next >